HMGA1 Activates FGFBP1 Transcription to Enhance Angiogenesis Induction and Tumor Progression via FGF2/FGFR1 Pathway
International Journal of Biological Sciences · 26.02.2026 · 22 (6) · 3013-3031
DOI: 10.7150/ijbs.109079 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, erschienen am 26.02.2026. Verfasst von Zhe Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Lab…. Hauptthemen laut MEDLINE: HMGA1a Protein, Receptor, Fibroblast Growth Factor, Type 1, Neovascularization, Pathologic, Fibroblast Growth Factor 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
High mobility group AT-hook 1 (HMGA1) is a chromatin regulator overexpressed in various cancers, often predicting poor outcomes. However, its role in head and neck squamous cell carcinoma (HNSCC) remains unclear. A hallmark of HNSCC is the rapid growth of its vasculature. Here, we identify an epigenetic mechanism whereby HMGA1 promotes tumor progression and angiogenesis via upregulation of fibroblast growth factor-binding protein 1 (FGFBP1). HMGA1 silencing suppressed oncogenic properties in vitro and reduced tumor initiating cells in HNSCC xenograft mice. RNA sequencing revealed that HMGA1 regulated transcriptional networks involved in tumor progression and angiogenesis, including the FGFBP1 gene. HMGA1 directly binds to the FGFBP1 promoter to induce its expression. This upregulation increased secretion of FGFBP1's target, FGF2. Interestingly, disrupting FGFBP1 via gene silencing or the FGFR1 inhibitor PD166866 recapitulated phenotypes observed with HMGA1 silencing. Blocking HMGA1, FGFBP1, or FGFR1 also reduced stromal formation and increased tumor necrosis. In human HNSCC, the combined analysis of HMGA1 and FGFBP1 provides a more detailed evaluation of patient prognosis. Our findings highlight a novel paradigm where HMGA1 and FGFBP1 drive tumor progression and angiogenesis, presenting them as potential therapeutic targets for HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Laboratory…
- Department of Oral and Maxillofacial Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
- School of Stomatology, Shandong First Medical University, Jinan, Shandong, 250117, China.
- Department of Oral and Maxillofacial Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China.
Zitieren
APA
Zhang, Z., Xiong, Y., Li, M., Wang, S., Liu, Z., Wang, G., Zhang, H., Yang, X., Liu, G., Zhang, D., Wu, H., & Huang, S. (2026). HMGA1 Activates FGFBP1 Transcription to Enhance Angiogenesis Induction and Tumor Progression via FGF2/FGFR1 Pathway. International Journal of Biological Sciences, 22(6), 3013-3031. https://doi.org/10.7150/ijbs.109079
Vancouver
Zhang Z, Xiong Y, Li M, Wang S, Liu Z, Wang G, et al. HMGA1 Activates FGFBP1 Transcription to Enhance Angiogenesis Induction and Tumor Progression via FGF2/FGFR1 Pathway. International Journal of Biological Sciences. 2026;22(6):3013-3031. doi:10.7150/ijbs.109079
BibTeX
@article{Zhang2026,
author = {Zhang, Zhe and Xiong, Yili and Li, Mingyang and Wang, Shengyao and Liu, Zhenxing and Wang, Guanduo and Zhang, Huanqing and Yang, Xiaojuan and Liu, Gangli and Zhang, Dongsheng and Wu, Haiwei and Huang, Shengyun},
title = {HMGA1 Activates FGFBP1 Transcription to Enhance Angiogenesis Induction and Tumor Progression via FGF2/FGFR1 Pathway},
journal = {International Journal of Biological Sciences},
year = {2026},
volume = {22},
number = {6},
pages = {3013--3031},
doi = {10.7150/ijbs.109079}
}
EUVIMED